Cancer chemotherapy: targeting folic acid synthesis

References

• FarberSCutlerECHawkinsJWHarrisonJHPeirceEC2ndLenzGGThe action of pteroylglutamic conjugates on manScience1947106276461962117831847
   PubMed Web of Science ®Google Scholar
• FarberSDiamondLKTemporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acidN Engl J Med19482382378779318860765
   PubMed Web of Science ®Google Scholar
• LiMCHertzRBergenstalDMTherapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonistsN Engl J Med19582592667413566422
   PubMed Web of Science ®Google Scholar
• KantarjianHThomasDO’BrienSLong-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaCancer2004101122788280115481055
   PubMed Web of Science ®Google Scholar
• BonadonnaGValagussaPMoliterniAZambettiMBrambillaCAdjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-upN Engl J Med1995332149019067877646
   PubMed Web of Science ®Google Scholar
• FuchsNBielackSSEplerDLong-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbsAnn Oncol1998988938999789613
   PubMed Web of Science ®Google Scholar
• FerreriAJReniMDell’OroSCombined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patientsOncology200160213414011244328
   PubMed Web of Science ®Google Scholar
• GuardiolaEPeyradeFChaigneauLResults of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancerEur J Cancer200440142071207615341981
   PubMed Web of Science ®Google Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• BuikhuisenWABurgersJAVincentADPemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?J Clin Oncol20102827e482e48320606096
   PubMed Web of Science ®Google Scholar
• ChenJSChaoYBangYJA phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinomaAnticancer Drugs201021877778420634689
   PubMed Web of Science ®Google Scholar
• SmitEFBurgersSABiesmaBRandomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancerJ Clin Oncol200927122038204519307503
   PubMed Web of Science ®Google Scholar
• FerreriAJGuerraERegazziMArea under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomasBr J Cancer200490235335814735176
   PubMed Web of Science ®Google Scholar
• JoergerMHuitemaADKrahenbuhlSMethotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: a pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trialBr J Cancer2010102467367720125159
   PubMed Web of Science ®Google Scholar
• ZhaoRMatherlyLHGoldmanIDMembrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissuesExpert Rev Mol Med200911e419173758
   PubMed Web of Science ®Google Scholar
• ChenGWrightJERosowskyADihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cellsMol Pharmacol19954847587657476904
   PubMed Web of Science ®Google Scholar
• GoldmanIDThe characteristics of the membrane transport of amethopterin and the naturally occurring folatesAnn N Y Acad Sci19711864004225289428
   PubMed Web of Science ®Google Scholar
• GoldmanIDLichtensteinNSOliverioVTCarrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cellJ Biol Chem196824319500750175303004
   PubMed Web of Science ®Google Scholar
• WhetstineJRFlatleyRMMatherlyLHThe human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoterBiochem J2002367Pt 362964012144527
   PubMed Web of Science ®Google Scholar
• RossJFChaudhuriPKRatnamMDifferential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implicationsCancer1994739243224437513252
   PubMed Web of Science ®Google Scholar
• WuMGunningWRatnamMExpression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervixCancer Epidemiol Biomarkers Prev19998977578210498396
   PubMed Web of Science ®Google Scholar
• ShenFWangHZhengXRatnamMExpression levels of functional folate receptors alpha and beta are related to the number of N-glycosylated sitesBiochem J1997327Pt 37597649581553
   PubMed Web of Science ®Google Scholar
• ShenFWuMRossJFMillerDRatnamMFolate receptor type gamma is primarily a secretory protein due to lack of an efficient signal for glycosylphosphatidylinositol modification: protein characterization and cell type specificityBiochemistry19953416566056657727426
   PubMed Web of Science ®Google Scholar
• RossJFWangHBehmFGFolate receptor type beta is a neutrophilic lineage marker and is differentially expressed in myeloid leukemiaCancer199985234835710023702
   PubMed Web of Science ®Google Scholar
• ShenFRossJFWangXRatnamMIdentification of a novel folate receptor, a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning, expression, immunoreactivity, and tissue specificityBiochemistry1994335120912158110752
   PubMed Web of Science ®Google Scholar
• WesterhofGRSchornagelJHKathmannICarrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activityMol Pharmacol19954834594717565626
   PubMed Web of Science ®Google Scholar
• AndrewsNCWhen is a heme transporter not a heme transporter? When it’s a folate transporterCell Metab2007515617189201
   PubMed Web of Science ®Google Scholar
• QiuAJansenMSakarisAIdentification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorptionCell2006127591792817129779
   PubMed Web of Science ®Google Scholar
• ShayeghiMLatunde-DadaGOOakhillJSIdentification of an intestinal heme transporterCell2005122578980116143108
   PubMed Web of Science ®Google Scholar
• KruhGDBelinskyMGThe MRP family of drug efflux pumpsOncogene200322477537755214576857
   PubMed Web of Science ®Google Scholar
• WielingaPHooijbergJHGunnarsdottirSThe human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolatesCancer Res200565104425443015899835
   PubMed Web of Science ®Google Scholar
• AllegraCJHoangKYehGCDrakeJCBaramJEvidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexateJ Biol Chem19872622813520135262443493
   PubMed Web of Science ®Google Scholar
• BaughCMKrumdieckCLNairMGPolygammaglutamyl metabolites of methotrexateBiochem Biophys Res Commun197352127344197190
   PubMed Web of Science ®Google Scholar
• CurtGAJolivetJCarneyDNDeterminants of the sensitivity of human small-cell lung cancer cell lines to methotrexateJ Clin Invest1985764132313292414316
   PubMed Web of Science ®Google Scholar
• FabreIFabreGGoldmanIDPolyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitroCancer Res1984448319031956204743
   PubMed Web of Science ®Google Scholar
• RosowskyAWrightJEVaidyaCMForschRAThe effect of side-chain, para-aminobenzoyl region, and B-ring modifications on dihydrofolate reductase binding, influx via the reduced folate carrier, and cytotoxicity of the potent nonpolyglutamatable antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithinePharmacol Ther200085319120510739874
   PubMed Web of Science ®Google Scholar
• BanerjeeDMayer-KuckukPCapiauxGBudak-AlpdoganTGorlickRBertinoJRNovel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthaseBiochim Biophys Acta200215872–316417312084458
   PubMed Web of Science ®Google Scholar
• OsbornMJFreemanMHuennekensFMInhibition of dihydrofolic reductase by aminopterin and amethopterinProc Soc Exp Biol Med195897242943113518295
   PubMed Web of Science ®Google Scholar
• JohnsonJMMeieringEMWrightJEPardoJRosowskyAWagnerGNMR solution structure of the antitumor compound PT523 and NADPH in the ternary complex with human dihydrofolate reductaseBiochemistry19973615439944119109647
   PubMed Web of Science ®Google Scholar
• BrigleKESpinellaMJSierraEEGoldmanIDCharacterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell lineJ Biol Chem19952703922974229797559435
   PubMed Web of Science ®Google Scholar
• DroriSJansenGMauritzRPetersGJAssarafYGClustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptakeJ Biol Chem200027540308553086310899164
   PubMed Web of Science ®Google Scholar
• JansenGMauritzRDroriSA structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistanceJ Biol Chem19982734630189301989804775
   PubMed Web of Science ®Google Scholar
• GorlickRGokerETrippettTDefective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expressionBlood1997893101310189028333
   PubMed Web of Science ®Google Scholar
• MatherlyLHTaubJWRavindranathYElevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemiaBlood19958525005097812005
   PubMed Web of Science ®Google Scholar
• RothemLAronheimAAssarafYGAlterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cellsJ Biol Chem2003278118935894112519783
   PubMed Web of Science ®Google Scholar
• ChangoAEmery-FillonNde CourcyGPA polymorphism (80G->A) in the reduced folate carrier gene and its associations with folate status and homocysteinemiaMol Genet Metab200070431031510993718
   PubMed Web of Science ®Google Scholar
• LaverdiereCChiassonSCosteaIMoghrabiAKrajinovicMPolymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemiaBlood2002100103832383412411325
   PubMed Web of Science ®Google Scholar
• YangRQinJHoangBHHealeyJHGorlickRPolymorphisms and methylation of the reduced folate carrier in osteosarcomaClin Orthop Relat Res200846692046205118528741
   PubMed Web of Science ®Google Scholar
• ToffoliGRussoAGalloAExpression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancerInt J Cancer19987921211269583724
   PubMed Web of Science ®Google Scholar
• HsuehCTDolnickBJRegulation of folate-binding protein gene expression by DNA methylation in methotrexate-resistant KB cellsBiochem Pharmacol1994476101910277511899
   PubMed Web of Science ®Google Scholar
• Diop-BoveNKWuJZhaoRLockerJGoldmanIDHypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell lineMol Cancer Ther2009882424243119671745
   PubMed Web of Science ®Google Scholar
• ChenZSLeeKWaltherSAnalysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux systemCancer Res200262113144315012036927
   PubMed Web of Science ®Google Scholar
• SirotnakFMWendelHGBornmannWGCo-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivoClin Cancer Res2000693705371210999764
   PubMed Web of Science ®Google Scholar
• BramEIferganIShafranABermanBJansenGAssarafYGMutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolatesCancer Chemother Pharmacol200658682683416612649
   PubMed Web of Science ®Google Scholar
• ShafranAIferganIBramEABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolatesCancer Res200565188414842216166320
   PubMed Web of Science ®Google Scholar
• GiffordAJKavallarisMMadafiglioJP-glycoprotein-mediated methotrexate resistance in CCRF-CEM sublines deficient in methotrexate accumulation due to a point mutation in the reduced folate carrier geneInt J Cancer19987821761819754649
   PubMed Web of Science ®Google Scholar
• HornsRCJrDowerWJSchimkeRTGene amplification in a leukemic patient treated with methotrexateJ Clin Oncol198421276583327
   PubMed Web of Science ®Google Scholar
• TrentJMBuickRNOlsonSHornsRCJrSchimkeRTCytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinomaJ Clin Oncol1984218156699660
   PubMed Web of Science ®Google Scholar
• LiWWLinJTTongWPTrippettTMBrennanMFBertinoJRMechanisms of natural resistance to antifolates in human soft tissue sarcomasCancer Res1992526143414381371715
   PubMed Web of Science ®Google Scholar
• SpencerHTSorrentinoBPPuiCHChunduruSKSleepSEBlakleyRLMutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexateLeukemia19961034394468642859
   PubMed Web of Science ®Google Scholar
• JolivetJCowanKHCurtGAClendeninnNJChabnerBAThe pharmacology and clinical use of methotrexateN Engl J Med198330918109411046353235
   PubMed Web of Science ®Google Scholar
• ErttmannRBielackSLandbeckGKinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapyCancer Chemother Pharmacol19851521011043874719
   PubMed Web of Science ®Google Scholar
• JoergerMHuitemaADvan den BongardHJDeterminants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patientsBr J Clin Pharmacol2006621718016842380
   PubMed Web of Science ®Google Scholar
• MoranRGRoles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overviewSemin Oncol1999262 Suppl 6243210598551
   PubMed Web of Science ®Google Scholar
• GalivanJRyanTRheeMYaoRChaveKGlutamyl hydrolase: properties and pharmacologic impactSemin Oncol1999262 Suppl 6333710598552
   PubMed Web of Science ®Google Scholar
• WidemannBCAdamsonPCUnderstanding and managing methotrexate nephrotoxicityOncologist200611669470316794248
   PubMed Web of Science ®Google Scholar
• von HoffDDPentaJSHelmanLJSlavikMIncidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administrationCancer Treat Rep1977614745748301783
   PubMedGoogle Scholar
• GreenMRChamberlainMCRenal dysfunction during and after high-dose methotrexateCancer Chemother Pharmacol200963459960418504579
   PubMed Web of Science ®Google Scholar
• SalongaDDanenbergKDJohnsonMColorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylaseClin Cancer Res2000641322132710778957
   PubMed Web of Science ®Google Scholar
• MaughanTJamesRKerrDExcess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimen in the palliative chemotherapy of advanced colorectal cancer (CRC): final results of MRC CRO6 [abstract]Ann Oncol200011Suppl 443
   Google Scholar
• CunninghamDZalcbergJMarounJEfficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trialsEur J Cancer200238447848611872339
   PubMed Web of Science ®Google Scholar
• ThomasRJWilliamsMGarcia-VargasJLessons learned from raltitrexed–quality assurance, patient education and intensive supportive drugs to optimise tolerabilityClin Oncol (R Coll Radiol)200315522723212924450
   PubMed Web of Science ®Google Scholar
• FordHECunninghamDSafety of raltitrexedLancet199935491921824182510577674
   PubMed Web of Science ®Google Scholar
• ClarkeSJBealePJRivoryLPClinical and preclinical pharmacokinetics of raltitrexedClin Pharmacokinet200039642944311192475
   PubMed Web of Science ®Google Scholar
• SirotnakFMDeGrawJIMoccioDMSamuelsLLGoutasLJNew folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic propertiesCancer Chemother Pharmacol198412118256690069
   PubMed Web of Science ®Google Scholar
• O’ConnorOAHorwitzSHamlinPPhase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignanciesJ Clin Oncol200927264357436419652067
   PubMed Web of Science ®Google Scholar
• ThompsonCAFDA approves pralatrexate for treatment of rare lymphomaAm J Health Syst Pharm20096621189019850775
   PubMed Web of Science ®Google Scholar
• O’ConnorOProBPinter-BrownLResults of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)J Clin Oncol200927Suppl 15449s Abstract 8561.
   Web of Science ®Google Scholar
• MatherlyLHHouZDengYHuman reduced folate carrier: translation of basic biology to cancer etiology and therapyCancer Metastasis Rev200726111112817334909
   PubMed Web of Science ®Google Scholar
• RayMSMuggiaFMLeichmanCGPhase I study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesisJ Natl Cancer Inst19938514115411598320744
   PubMedGoogle Scholar
• JolivetJJansenGPetersGJPinardMFSchornagelJHLeucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexateBiochem Pharmacol19944746596657510479
   PubMed Web of Science ®Google Scholar
• GrantSCKrisMGYoungCWSirotnakFMEdatrexate, an antifolate with antitumor activity: a reviewCancer Invest199311136458422595
   PubMed Web of Science ®Google Scholar
• KrisMGKinahanJJGrallaRJPhase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancerCancer Res19884819557355793416310
   PubMed Web of Science ®Google Scholar
• SchornagelJHVerweijJde MulderPHRandomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group studyJ Clin Oncol1995137164916557602354
   PubMed Web of Science ®Google Scholar
• RosowskyAPT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamatesCurr Med Chem19996432935210101216
   PubMed Web of Science ®Google Scholar
• GilesFRizzieriDAGeorgeSA phase I study of talvesta (talotrexin) in relapsed or refractory leukemia or myelodysplastic syndromeBlood (ASH Annual Meeting Abstracts)2006108111968
   Google Scholar
• MarshallJLDeLapRJClinical pharmacokinetics and pharmacology of trimetrexateClin Pharmacokinet19942631902008194282
   PubMed Web of Science ®Google Scholar
• FlemingGFSchilskyRLAntifolates: the next generationSemin Oncol19921967077191462168
   PubMed Web of Science ®Google Scholar
• TakimotoCHNew antifolates: pharmacology and clinical applicationsOncologist199611 and 2688110387971
   PubMedGoogle Scholar
• TaylorIWSlowiaczekPFriedlanderMLTattersallMHSelective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptakeCancer Res19854539789823971388
   PubMed Web of Science ®Google Scholar
• AdamsonPCBalisFMMiserJPediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent scheduleCancer Res19925235215241732038
   PubMed Web of Science ®Google Scholar
• SakoffJAAcklandSPThymidylate synthase inhibition induces S-phase arrest, biphasic mitochondrial alterations and caspase-dependent apoptosis in leukaemia cellsCancer Chemother Pharmacol200046647748711138461
   PubMed Web of Science ®Google Scholar
• van der WiltCLSmidKPetersGJEffects of antifolates on the binding of 5-fluoro-2′-deoxyuridine monophosphate to thymidylate synthaseBiochem Pharmacol200264466967512167486
   PubMed Web of Science ®Google Scholar
• JhawerMRosenLDanceyJPhase II trial of nolatrexed dihydrochloride [Thymitaq, AG 337] in patients with advanced hepatocellular carcinomaInvest New Drugs2007251859416957834
   PubMed Web of Science ®Google Scholar
• HannaNShepherdFAFossellaFVRandomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyJ Clin Oncol20042291589159715117980
   PubMed Web of Science ®Google Scholar
• SelvaggiGScagliottiGVHistologic subtype in NSCLC: does it matter?Oncology (Williston Park)200923131133114020043461
   PubMed Web of Science ®Google Scholar
• NiyikizaCHanauskeARRusthovenJJPemetrexed safety and dosing strategySemin Oncol2002296 Suppl 18242912571807
   PubMed Web of Science ®Google Scholar
• GoldmanIDZhaoRMolecular, biochemical, and cellular pharmacology of pemetrexedSemin Oncol2002296 Suppl 1831712571805
   PubMed Web of Science ®Google Scholar
• PizzornoGMorosonBACashmoreARMultifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEMCancer Res19955535665737834626
   PubMed Web of Science ®Google Scholar
• RheeMSRyanTJGalivanJGlutamyl hydrolase and the multitargeted antifolate LY231514Cancer Chemother Pharmacol199944542743210501918
   PubMed Web of Science ®Google Scholar
• de JongeMJPuntCJSparreboomAPhase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumorsJ Clin Oncol20022071923193111919253
   PubMed Web of Science ®Google Scholar
• CalvertAHBiochemical pharmacology of pemetrexedOncology (Williston Park)20041813 Suppl 8131715655931
   PubMedGoogle Scholar
• DickgreberNJSorensenJBPaz-AresLGPemetrexed safety and pharmacokinetics in patients with third-space fluidClin Cancer Res201016102872288020460481
   PubMed Web of Science ®Google Scholar
• BrandesJCGrossmanSAAhmadHAlteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literatureCancer Invest200624328328716809156
   PubMed Web of Science ®Google Scholar
• NiyikizaCBakerSDSeitzDEHomocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapyMol Cancer Ther20021754555212479273
   PubMed Web of Science ®Google Scholar